Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

For Ichnos Glenmark Innovation, good things come in threes. The alliance between Ichnos Sciences and Glenmark Pharmaceuticals ...

The update stated that the implant’s cobalt-chromium alloy carries an increased risk of femur fractures following a procedure ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...

Five months after Rakovina Therapeutics pivoted toward artificial intelligence, the cancer-focused biotech has joined forces ...